References

1. POMALYST [package insert]. Summit, NJ: Celgene Corp; 2020.

2. Schneider JW, Dittmer DP. Diagnosis and treatment of Kaposi sarcoma. *Am J Clin Dermatol*. 2017;18(4):529-539.

3. Polizzotto MN, Uldrick TS, Wyvill KM, et al. Pomalidomide for symptomatic Kaposi's sarcoma in people with and without HIV infection: A Phase I/II study. *J Clin Oncol.* 2016;34(34):4125-4131.

4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for AIDS Related Kaposi Sarcoma. V.1.2020.© National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed February 27, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

POMALYST ®, POMALYST REMS®, Celgene Patient Support® and associated logos are trademarks of Celgene Corporation, a Bristol Myers Squibb Company.

© 2020 Bristol-Myers Squibb Company. 05/20 US-POM-20-0067

Bristol Myers Squibb™